SG&A Efficiency Analysis: Comparing Iovance Biotherapeutics, Inc. and MiMedx Group, Inc.

Biotech SG&A Trends: Iovance vs. MiMedx

__timestampIovance Biotherapeutics, Inc.MiMedx Group, Inc.
Wednesday, January 1, 2014933577290480000
Thursday, January 1, 201512390000133384000
Friday, January 1, 201625602000179997000
Sunday, January 1, 201721262000220119000
Monday, January 1, 201828430000258528000
Tuesday, January 1, 201940849000198205000
Wednesday, January 1, 202060210000181022000
Friday, January 1, 202183664000198359000
Saturday, January 1, 2022104097000208789000
Sunday, January 1, 2023106916000211124000
Loading chart...

Unleashing the power of data

SG&A Efficiency: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing operational expenses is crucial for sustainability and growth. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Iovance Biotherapeutics, Inc. and MiMedx Group, Inc. over a decade, from 2014 to 2023.

Iovance Biotherapeutics has seen a significant increase in SG&A expenses, growing by over 1,000% from 2014 to 2023. This reflects their aggressive expansion and investment in research and development. In contrast, MiMedx Group's SG&A expenses have been more stable, with a 133% increase over the same period, indicating a more conservative approach to operational spending.

Understanding these trends provides valuable insights into each company's strategic priorities and financial health. Investors and stakeholders can use this data to assess the efficiency and effectiveness of each company's management strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025